Dyne Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Dyne Therapeutics, Inc. (DYN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 9.06 million shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2022-03-10
- Dyne Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2021-03-31 was 7.56M shares, a 39.43% decline year-over-year.
- Dyne Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2020-03-31 was 12.48M shares.
- Dyne Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 9.06M shares, a 25.96% increase from fiscal 2020.
- Dyne Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 7.20M shares, a 33.14% decline from fiscal 2019.
- Dyne Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2019 was 10.76M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2021-12-31 | 9.06M shares 10-K · filed 2022-03-10 | |||
| 2021-09-30 | 8.01M shares 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | 7.92M shares 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | 7.56M shares 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | 7.20M shares 10-K · filed 2022-03-10 | |||
| 2020-09-30 | 7.15M shares 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | 12.67M shares 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 12.48M shares 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 10.76M shares 10-K · filed 2021-03-04 | |||
| 2019-09-30 | 10.84M shares 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |